Suppr超能文献

乙琥胺可逆转紫杉醇和长春新碱引起的疼痛性周围神经病变。

Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy.

作者信息

Flatters Sarah J L, Bennett Gary J

机构信息

Anaesthesia Research Unit, McIntyre Building, Room 1213, McGill University, 3655 Promenade Sir William Osler, Montreal, Qc, Canada H3G 1Y6.

出版信息

Pain. 2004 May;109(1-2):150-61. doi: 10.1016/j.pain.2004.01.029.

Abstract

Paclitaxel (Taxol) is one of the most effective and frequently used chemotherapeutics for the treatment of solid tumours. However, paclitaxel produces peripheral neurotoxicity with patients reporting sensory abnormalities and neuropathic pain during and often persisting after paclitaxel therapy. The mechanisms underlying this dose-limiting side effect are currently unknown and there are no validated drugs for its prevention or control. Male Sprague-Dawley rats received four intraperitoneal (i.p.) injections on alternate days of 2 mg/kg paclitaxel. Behavioural assessment using von Frey filaments and acetone showed that such paclitaxel treatment induced a pronounced mechanical and cold allodynia/hyperalgesia. Thus these studies aim to test potential analgesics on established paclitaxel-induced pain. Paclitaxel-induced pain appears to be relatively resistant to opioid therapy i.p. 4 mg/kg morphine was ineffective and i.p. 8 mg/kg morphine only elicited up to a 50% reversal of mechanical allodynia/hyperalgesia. Interestingly, a maximally tolerated dose (i.p. 0.2 mg/kg) of the potent NMDA receptor antagonist MK-801 produced no significant reversal of the mechanical allodynia/hyperalgesia suggesting that NMDA receptors have little role in paclitaxel-induced pain. Ethosuximide (i.p. 450 mg/kg) an anti-epileptic and relatively selective T-type calcium channel blocker elicited a near complete reversal of mechanical allodynia/hyperalgesia. Repetitive dosing with ethosuximide (i.p. 100 or 300 mg/kg daily for 3 days) showed a dose-related consistent reversal of mechanical allodynia/hyperalgesia with no evidence of tolerance. Ethosuximide (i.p. 300 mg/kg) also reversed paclitaxel-induced cold allodynia and vincristine-induced mechanical allodynia/hyperalgesia. These data suggest that T-type calcium channels may play a role in chemotherapy-induced neuropathy and moreover identify ethosuximide as a new potential treatment for chemotherapy-induced pain.

摘要

紫杉醇(泰素)是治疗实体瘤最有效且常用的化疗药物之一。然而,紫杉醇会产生外周神经毒性,患者在紫杉醇治疗期间会出现感觉异常和神经性疼痛,且这种疼痛在治疗后常常持续存在。这种剂量限制性副作用的潜在机制目前尚不清楚,并且没有经过验证的药物可用于预防或控制。雄性斯普拉格 - 道利大鼠每隔一天接受4次腹腔注射2mg/kg紫杉醇。使用von Frey细丝和丙酮进行的行为评估表明,这种紫杉醇治疗会引起明显的机械性和冷觉异常性疼痛/痛觉过敏。因此,这些研究旨在测试针对已确立的紫杉醇诱导疼痛的潜在镇痛药。紫杉醇诱导的疼痛似乎对阿片类药物治疗相对耐药,腹腔注射4mg/kg吗啡无效,腹腔注射8mg/kg吗啡仅能使机械性异常性疼痛/痛觉过敏最多逆转50%。有趣的是,强效NMDA受体拮抗剂MK - 801的最大耐受剂量(腹腔注射0.2mg/kg)并未使机械性异常性疼痛/痛觉过敏产生明显逆转,这表明NMDA受体在紫杉醇诱导的疼痛中作用不大。乙琥胺(腹腔注射450mg/kg)是一种抗癫痫药且是相对选择性的T型钙通道阻滞剂,可使机械性异常性疼痛/痛觉过敏几乎完全逆转。重复给予乙琥胺(腹腔注射100或300mg/kg,每日1次,共3天)显示出与剂量相关的持续性机械性异常性疼痛/痛觉过敏逆转,且没有耐受性的证据。乙琥胺(腹腔注射300mg/kg)还可逆转紫杉醇诱导的冷觉异常性疼痛以及长春新碱诱导的机械性异常性疼痛/痛觉过敏。这些数据表明,T型钙通道可能在化疗诱导的神经病变中起作用,而且确定乙琥胺是化疗诱导疼痛的一种新的潜在治疗药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验